MARINUS PHARMACEUTICALS, INC. (MRNS)
Marinus Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of neuropsychiatric therapeutics. Its clinical stage drug product candidate, ganaxolone, is a positive allosteric modulator being developed in three different dose forms: intravenous, capsule, and liquid. The company was founded in August 2003 and is headquartered in Radnor, PA.
Address
5 RADNOR CORPORATE CENTER SUITE 500
RADNOR, PA 19087
Founded
2003
Number of Employees
165
Website
http://www.marinuspharma.com
Buyback
| Buyback Data | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | Average |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $ Amount Purchased ($ in 000s ) |
- | - | - | - | - | - | - | - | $55 | - | - | $55 |
| Average Price | - | - | - | - | - | - | - | - | $8.41 | - | - | $8.41 |
| # Shares Purchased | - | - | - | - | - | - | - | - | 6,497 | - | - | 6,497 |
| Buyback Performance | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | Average |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Return to Date | - | - | - | - | - | - | - | - | -88.1% | - | - | -88.1% |
| S&P 500 Return to Date | - | - | - | - | - | - | - | - | 37.3% | - | - | 37.3% |
| Excess Total Return | - | - | - | - | - | - | - | - | -125.4% | - | - | -125.4% |
| Quartile Rank |
|
|
|
|
|
|
|
|
|
|
|
|
| Percentile Rank | - | - | - | - | - | - | - | - | 2% | - | - | 3% |
Buyback returns calculated using weighted average buyback price over the last 10 years and comparing to current day stock price value. S&P 500 used as benchmark for excess return.
Insider Transactions
Filters
Keyboard Shortcuts: Show (a) | Close (Esc)
Never miss an email alert when insiders at MRNS make a trade.
Creating a free account takes less than one minute